

Dr. MARCO CIPPITELLI

**Curriculum Vitae****Part I – General Information**

Full Name	Marco Cippitelli
Citizenship	Italian
Spoken Languages	Italian, English.

**Part II – Education**

Type	Year	Institution	Notes (Degree, Experience,...)
University graduation	1990	Univ. La Sapienza – Rome, Italy.	Master degree in Biological Sciences – “Summa cum laude”.
Pre-doctorate training	1991-1992	Univ. La Sapienza – Rome, Italy.	1° year Post-graduate internship (Experimental Medicine)
PhD	1991-1995	Univ. La Sapienza – Rome, Italy.	PhD degree in Experimental Medicine.
Post-graduate studies	1992-1995	National Cancer Institute (NCI) Frederick, Maryland, USA. "Molecular Immunology Section" (Lab. of Experimental Immunology).	Molecular Immunology. Transcriptional regulation.
Post-doctorate fellowship.	2000	Univ. La Sapienza – Rome, Italy.	Molecular Immunology. Transcriptional regulation.

**Part III – Appointments**

## IIIA – Academic Appointments

Start	End	Institution	Position
2000	2007	Univ. La Sapienza – Rome, Italy.	Researcher - General Pathology (Med-04).
2007	2021	Univ. La Sapienza – Rome, Italy.	Associate Professor - General Pathology (Med-04).

## IIIB – Other Appointments

Start	End	Institution	Position
1992	1995	National Cancer Institute (NCI) Frederick, Maryland, USA. "Molecular Immunology Section" (Lab. of Experimental Immunology).	Visiting Scientist/Employed at NCI-FCRDC - SAIC NIH.
1996	2000	Laboratory of Pathophysiology, CRS, Regina Elena Cancer Institute, Rome, (IT).	Research Scientist.
2000	2013	Laboratory of Pathophysiology and Immunology, CRS, Regina Elena Cancer Institute, Rome (IT).	Research Associate.
2014	2023	Abilitazione Scientifica Nazionale (Bando 2012)	I fascia SC 06/N1 – Med/46
2018	2027	Abilitazione Scientifica Nazionale (Bando 2016)	I fascia SC 06/A2 – Med/04

## Part IV – Teaching experience

Year	Institution	Lecture/Course
2000 - 2021	Univ. La Sapienza – Rome, Italy. Facoltà di Farmacia e Medicina.	Immunologia e Immunopatologia (Laurea Magistrale in Medicina e Chirurgia).
2012 - 2021	Univ. La Sapienza – Rome, Italy. Facoltà di Medicina e Odontoiatria.	Patologia Generale (Lauree Triennali - Tecnici di Neurofisiopatologia).
2018 - 2021	Univ. La Sapienza – Rome, Italy. Facoltà di Medicina e Odontoiatria	Patologia Generale (Laurea Magistrale in Infermieristica e Ostetricia).
2000 - 2021	Univ. La Sapienza – Rome, Italy. Facoltà di Medicina e Odontoiatria	Immunologia e Immunopatologia + Tecniche di Laboratorio (Lauree Triennali – Tecniche di Laboratorio Biomedico). Coordinatore di corso Integrato – Basi Fisiopatologiche delle Malattie.
2018 - 2021	Univ. La Sapienza – Rome, Italy. Facoltà di Medicina e Odontoiatria	Patologia Generale (Lauree Triennali - Infermieristica).
2021	Univ. La Sapienza – Rome, Italy. Facoltà di Medicina e Odontoiatria	Immunology and Immunopathology (Laurea Magistrale in Medicina e Chirurgia – Corso in Inglese).
Dal 2006:	Univ. La Sapienza – Rome, Italy. Facoltà di Farmacia e Medicina.	Componente del Collegio dei Docenti per il Dottorato di Ricerca in: Scienze Immunologiche (2006-2010), Scienze Immunologiche - Ematologiche e Reumatologiche (2011-2016), Innovation in Immuno-Mediated and Hematological Disorders (2019-2021).

## Part V - Society memberships, Awards and Honors

Year	Title
Since 2008	Effective Member – Società Italiana Immunologia Clinica e Allergologia (SIICA)

## Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Grant value
2002/2004	Identificazione di molecole coinvolte nello stress ossidativo quali bersagli per la terapia antitumorale.	Ministry of Health Project. Prot. SAR/6015	56810 eur
2001/2002	Interazioni tra la citochina TGF-beta e l'ormone Vitamina D3 nei meccanismi di regolazione del ciclo cellulare. Analisi della convergenza funzionale tra il recettore nucleare della Vitamina D3 (VDR), e la proteina SMAD-3.	Program "CNR-Agenzia 2000" – Codice: CNRC008B98_005.	7750 eur
2006/2008	Analysis of GITR gene expression in T lymphocytes and specific pharmacological modulation.	Ministry of the University, PRIN – Codice: C26F050211	42900 eur
2008/2010	Microenvironment and responses to therapy in Multiple Myeloma: alteration of pathologic osteoclastogenic potential.	Ministry of the University, PRIN - Codice: 2008SKTMME_004	40700 eur
2011/2012	Studio del ruolo dei granulociti neutrofili e delle cellule natural killer nello sviluppo delle osteoartriti infiammatorie	Ricerche Universitarie - FARI - Univ. La Sapienza, Roma. Codice: C26I11L32J	6000 eur
2010/2013	Multiple Myeloma Immune Microenvironment as Target to Understand and Overcome Mechanisms of Clinical Relapse and Resistance.	Ministry of the University, PRIN - Codice: 2010NECHBX_004.	145000 eur
2015/2016	Cereblon, the molecular target of the Immunomodulatory Drugs (IMiDs), as a regulator of Natural Killer Cell functions.	Ricerca Scientifica Ateneo, Univ. La Sapienza, Rome, Italy. Codice: C26A14H9R2.	4500 eur
2017/2022	RNASET2 as new player in the modulation of the innate immune system in cancer and autoimmunity: potential diagnostic and therapeutic implications	Ministry of the University, PRIN – Codice: 2017NTK4HY_005	149134 eur

2019/2021	Harnessing NK cells by genetic and epigenetic rerouting to overcome Multiple Myeloma immune evasion	Progetti di Ricerca Grandi Ateneo, Univ. La Sapienza, Rome, Italy. – Codice: 2018/RG11816426E8448B	30000 eur
-----------	---	--	-----------

## Part VII – Research Activities

### Keywords

### Brief Description:

Transcriptional Regulation
Nuclear Receptors
Apoptosis
Natural Killer
Chemotherapy
Multiple Myeloma

Dr. Cippitelli research activity has been mainly conducted in the field of transcriptional regulation and tumor immunology, aimed at understanding the mechanisms underlying the regulation of genes involved in NK cell antitumor effector functions.

#### Main areas of interest over the years:

1992/95: - Study of the transcriptional events that regulate IFN-gamma, IL-2 and IL-4 genes in activated T cells.

1996/98: - Study of the molecular mechanisms that modulate the transcription of the IFN-gamma and IL-12 genes, by the nuclear receptor VDR in T cells and monocytes/dendritic cells.

- Study of the signaling pathways involved in the activation of the IFN-gamma gene, mediated by integrin receptors, in NK cells.

- Study of the anti-apoptotic protein Bcl-2, as a molecule able to regulate NF-kB transcriptional activity and MMP-9 metallo-proteinase gene expression, in human breast carcinoma cells.

2000/2003: - Study of the molecular mechanisms that modulate the transcription and function of the FasL gene by different nuclear receptors and specific ligands in activated T cells: VDR, PPAR-gamma.

2003/2005: - Study of the molecular mechanisms mediated by hyperthermia, able to enhance the transcription of the FasL gene in activated T cells.

2005/2007: - Study of the molecular mechanisms that modulate the transcription and function of the RANK-L and TRAIL genes by nuclear receptors and specific ligands in activated T cells: modulation mediated by activators of PPAR-gamma.

2007/Present: - Study of the molecular mechanisms that regulate the transcription, expression and function of different NK cell-activating ligands by different chemotherapies, in Multiple Myeloma cells.

2019/Present: - Study of the role mediated by the ribonuclease RNASET2 in the regulation of the immune innate response-mediated mechanisms against multiple myeloma.

**Part VIII – Summary of Scientific Achievements**

Product type	Number	Data Base	Start	End
Papers [international]	61	(Scopus)	1992	2021
Papers [national]	/			
Books [scientific]	/			
Books [teaching]	/			

Total Impact factor **	374,453 (Scopus)
Average Impact Factor **	6.13 (Scopus)
Total Citations	3835 (Scopus)
Average Citations per Product	62,86 (Scopus)
Hirsch (H) index	32 (Scopus)
Normalized H index*	1.28
Average Impact Factor **	6.13

\* H index divided by the academic seniority. (PhD in 1996)

\*\* Calculated in relation to the publication year

## Part IX – Selected Publications

### Dr. Marco Cippitelli - Selected Publications (16)

IF calculated in relation to the publication year. **Citations: (Scopus)**

1) **Cippitelli M.** and Santoni A.

Vitamin D3: a transcriptional modulator of the interferon-gamma gene.

EUR J IMMUNOL. (1998) Oct;28(10):3017-30. **IF: 5.438 Citations: 241**

2) Ricca A., Biroccio A., Del Bufalo D., Mackay AR., Santoni A. and **Cippitelli M.**

Bcl-2 overexpression enhances NF-kB activity and induces MMP-9 transcription in human MCF7ADR breast cancer cells.

INT. J. CANCER. (2000) 86, 188. **IF: 3.918 Citations: 91**

3) **Cippitelli M.**, Fionda C., Di Bona D., Di Rosa F., Lupo A., Piccoli M., Frati L. and Santoni A.

Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes.

J. IMMUNOL. (2002) 168(3), 1154. **IF: 7.014 Citations: 66**

4) **Cippitelli M.**, Fionda C., Di Bona D., Lupo A., Piccoli M., Frati L. and Santoni A.

The cyclopentenone-type prostaglandin 15-deoxy-delta12,14-prostaglandin J2 inhibits CD95 ligand gene expression in T lymphocytes: interference with promoter activation via peroxisome proliferator-activated receptor-gamma-independent mechanisms.

J. IMMUNOL. (2003) 170(9), 4578. **IF: 6.702 Citations: 30**

5) **Cippitelli M.**, Fionda C., Di Bona D., Piccoli M., Frati L. and Santoni A.

Hyperthermia enhances CD95-Ligand gene expression in T lymphocytes.

J. IMMUNOL. (2005) 174(1), 223. **IF: 6.387 Citations: 32**

6) Fionda C., Nappi F., Piccoli M., Frati L., Santoni A. and **Cippitelli M.**

15-deoxy-delta12,14-Prostaglandin J2 negatively regulates rankl gene expression in activated T lymphocytes: Role of NF-kB and Early Growth Response transcription factors.

J. IMMUNOL. (2007) 178(7):4039-50 **IF: 6.068 Citations: 14**

7) Fionda C., Nappi F., Piccoli M., Frati L., Santoni A. and **Cippitelli M.**

Inhibition of trail gene expression by cyclopentenonic prostaglandin 15-deoxy-delta12,14-prostaglandin J2 in T lymphocytes.

MOL PHARMACOL. (2007) Nov;72(5):1246-57. **IF: 4.088 Citations: 13**

8) Fionda C., Soriani A., Malgarini G., Iannitto ML., Santoni A. and **Cippitelli M.**

Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.

J. IMMUNOL. (2009) 183(7):4385-4394. **IF: 5.646 Citations: 66**

9) Cinzia Fionda, Giulia Malgarini, Alessandra Soriani, Alessandra Zingoni, Francesca Cecere, Maria Luisa Iannitto, Maria Rosaria Ricciardi, V. Federico, Maria Teresa Petrucci, Angela Santoni and **Marco Cippitelli.**

Inhibition of Glycogen Synthase Kinase-3 Increases NKG2D Ligand MICA Expression and Sensitivity to NK Cell-Mediated Cytotoxicity in Multiple Myeloma Cells: Role of STAT3.

JOURNAL OF IMMUNOLOGY (2013) vol. 190, p. 6662-6672. **IF: 5.362 Citations: 51**

10) C. Fionda, MP. Abruzzese, A. Zingoni, A. Soriani, BM. Ricci, R. Molfetta, R. Paolini, A. Santoni and **M. Cippitelli.**

Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.

BMC CANCER (2015) vol. 15:17. **IF: 3.265 Citations: 38**

11) Fionda C, Abruzzese MP, Zingoni A, Cecere F, Vulpis E, Peruzzi G, Soriani A, Molfetta R, Paolini R, Ricciardi MR, Petrucci MT, Santoni A and **Cippitelli M**.

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.

ONCOTARGET. (2015) Sep 15;6(27):23609-30. **IF: 5.008 Citations: 55**

12) Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, Borrelli C, Zitti B, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A and **Cippitelli M**.

Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.

J HEMATOL ONCOL. (2016) Dec 1;9(1):134. **IF: 6.350 Citations: 49**

13) Bilotta MT, Abruzzese MP, Molfetta R, Scarno G, Fionda C, Zingoni A, Soriani A, Garofalo T, Petrucci MT, Ricciardi MR, Paolini R, Santoni A and **Cippitelli M**.

Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.

FASEB J. (2019) May 24:fj201900319R. doi: 10.1096/fj.201900319R. **IF: 4.966 Citations: 9**

14) Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A and **Cippitelli M**.

The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors.

CELL DEATH DIS. (2019) Apr 11;10(4):324. doi: 10.1038/s41419-019-1562-9. **IF: 6.304 Citations: 9**

15) Fionda C, Di Bona D, Kosta A, Stabile H, Santoni A and **Cippitelli M**.

The POU-Domain Transcription Factor Oct-6/POU3F1 as a Regulator of Cellular Response to Genotoxic Stress.

CANCERS (Basel). (2019) Jun 11;11(6). pii: E810. doi: 10.3390/cancers11060810. **IF: 6.126 Citations: 1**

16) Petillo S, Capuano C, Molfetta R, Fionda C, Mekhloufi A, Pighi C, Antonangeli F, Zingoni A, Soriani A, Petrucci MT, Galandrini R, Paolini R, Santoni A and **Cippitelli M**.

Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.

CELL DEATH DIS. (2021) Sep 4;12(9):836. doi: 10.1038/s41419-021-04104-w. **IF: 8.469 Citations: /**

---

**Part X – Dr. Marco Cippitelli - All Publications (Scopus)**

1 - Sara Petillo, Cristina Capuano, Rosa Molfetta, Cinzia Fionda, Abdelilah Mekhloufi, Chiara Pighi, Fabrizio Antonangeli, Alessandra Zingoni, Alessandra Soriani, Maria Teresa Petrucci, Ricciarda Galandrini, Rossella Paolini, Angela Santoni and **Marco Cippitelli**.

Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.

**Cell Death and Disease**, 2021, 12(9), 836 **N° Citations: /** (Scopus)

2 - Fionda C, Stabile H, Molfetta R, Kosta A, Peruzzi G, Ruggeri S, Zingoni A, Capuano C, Soriani A, Paolini R, Gismondi A, **Cippitelli M**, Santoni A.

Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation.

**Eur J Immunol**. 2021 Aug 15. doi: 10.1002/eji.202149269. **N° Citations: /** (Scopus)

3 - **Cippitelli M**, Stabile H, Kosta A, Petillo S, Gismondi A, Santoni A, Fionda C.

Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them.

**Int J Mol Sci**. 2021 Jan 22;22(3):1103. doi: 10.3390/ijms22031103. **N° Citations: 2** (Scopus)

4 - Bilotta MT, Petillo S, Santoni A, **Cippitelli M**.

Liver X Receptors: Regulators of Cholesterol Metabolism, Inflammation, Autoimmunity, and Cancer.

**Front Immunol**. 2020 Nov 3;11:584303. doi: 10.3389/fimmu.2020.584303. eCollection 2020. **N° Citations: 7** (Scopus)

5 - Mekhloufi A, Kosta A, Stabile H, Molfetta R, Zingoni A, Soriani A, **Cippitelli M**, Paolini R, Gismondi A, Ricciardi MR, Petrucci MT, Masuelli L, Caracciolo G, Palchetti S, Santoni A, Fionda C.

Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF- $\kappa$ B Transcription Factor.

**Cancers** (Basel). 2020 Feb 13;12(2):440. doi: 10.3390/cancers12020440. **N° Citations: 8** (Scopus)

6 - Molfetta R, Zitti B, Lecce M, Milito ND, Stabile H, Fionda C, **Cippitelli M**, Gismondi A, Santoni A, Paolini R.

CD155: A Multi-Functional Molecule in Tumor Progression.

**Int J Mol Sci**. 2020 Jan 30;21(3):922. doi: 10.3390/ijms21030922. **N° Citations: 9** (Scopus)

7 - Fionda C, Stabile H, Cerboni C, Soriani A, Gismondi A, **Cippitelli M**, Santoni A.

Hitting More Birds with a Stone: Impact of TGF- $\beta$  on ILC Activity in Cancer.

**J Clin Med**. 2020 Jan 5;9(1):143. doi: 10.3390/jcm9010143. **N° Citations: 8** (Scopus)

8 - Acquati F, Mortara L, De Vito A, Baci D, Albini A, **Cippitelli M**, Taramelli R, Noonan DM. Innate Immune Response Regulation by the Human RNASET2 Tumor Suppressor Gene.

**Front Immunol**. 2019 Nov 5;10:2587. doi: 10.3389/fimmu.2019.02587. eCollection 2019. **N° Citations: 10** (Scopus)

9 - Bilotta MT, Abruzzese MP, Molfetta R, Scarno G, Fionda C, Zingoni A, Soriani A, Garofalo T, Petrucci MT, Ricciardi MR, Paolini R, Santoni A, **Cippitelli M**.

Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.

**FASEB J**. 2019 Aug;33(8):9489-9504. doi: 10.1096/fj.201900319R. Epub 2019 May 24. **N° Citations: 9** (Scopus)



- 10 - Fionda C, Di Bona D, Kosta A, Stabile H, Santoni A, **Cippitelli M**.  
The POU-Domain Transcription Factor Oct-6/POU3F1 as a Regulator of Cellular Response to Genotoxic Stress.  
**Cancers** (Basel). 2019 Jun 11;11(6):810. doi: 10.3390/cancers11060810. **N° Citations: 1** (Scopus)
- 11 - Molfetta R, Milito ND, Zitti B, Lecce M, Fionda C, **Cippitelli M**, Santoni A, Paolini R.  
The Ubiquitin-proteasome pathway regulates Nectin2/CD112 expression and impairs NK cell recognition and killing.  
**Eur J Immunol**. 2019 Jun;49(6):873-883. doi: 10.1002/eji.201847848. Epub 2019 Mar 27. **N° Citations: 10** (Scopus)
- 12 - Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, **Cippitelli M**.  
The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors.  
**Cell Death Dis**. 2019 Apr 11;10(4):324. doi: 10.1038/s41419-019-1562-9. **N° Citations: 9** (Scopus)
- 13 - Vulpis E, Stabile H, Soriani A, Fionda C, Petrucci MT, Mariggio' E, Ricciardi MR, **Cippitelli M**, Gismondi A, Santoni A, Zingoni A.  
Key Role of the CD56lowCD16low Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells.  
**Cancers** (Basel). 2018 Nov 29;10(12):473. doi: 10.3390/cancers10120473. **N° Citations: 14** (Scopus)
- 14 - Fionda C, Stabile H, Molfetta R, Soriani A, Bernardini G, Zingoni A, Gismondi A, Paolini R, **Cippitelli M**, Santoni A.  
Translating the anti-myeloma activity of Natural Killer cells into clinical application.  
**Cancer Treat Rev**. 2018 Nov;70:255-264. doi: 10.1016/j.ctrv.2018.10.005. Epub 2018 Oct 10. **N° Citations: 15** (Scopus)
- 15 - Borrelli C, Ricci B, Vulpis E, Fionda C, Ricciardi MR, Petrucci MT, Masuelli L, Peri A, **Cippitelli M**, Zingoni A, Santoni A, Soriani A.  
Drug-Induced Senescent Multiple Myeloma Cells Elicit NK Cell Proliferation by Direct or Exosome-Mediated IL15 Trans-Presentation.  
**Cancer Immunol Res**. 2018 Jul;6(7):860-869. doi: 10.1158/2326-6066.CIR-17-0604. Epub 2018 Apr 24. **N° Citations: 25** (Scopus)
- 16 - Zingoni A, Vulpis E, Cecere F, Amendola MG, Fuerst D, Saribekyan T, Achour A, Sandalova T, Nardone I, Peri A, Soriani A, Fionda C, Mariggio' E, Petrucci MT, Ricciardi MR, Mytilineos J, **Cippitelli M**, Cerboni C, Santoni A.  
MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.  
**Front Immunol**. 2018 May 1;9:926. doi: 10.3389/fimmu.2018.00926. eCollection 2018 **N° Citations: 18** (Scopus)
- 17 - Zingoni A, Molfetta R, Fionda C, Soriani A, Paolini R, **Cippitelli M**, Cerboni C, Santoni A.  
NKG2D and Its Ligands: "One for All, All for One".  
**Front Immunol**. 2018 Mar 12;9:476. doi: 10.3389/fimmu.2018.00476. eCollection 2018. **N° Citations: 83** (Scopus)
- 18 - Zingoni A, Fionda C, Borrelli C, **Cippitelli M**, Santoni A, Soriani A.  
Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.  
**Front Immunol**. 2017 Sep 25;8:1194. doi: 10.3389/fimmu.2017.01194. eCollection 2017. **N° Citations: 61** (Scopus)

19 - Zitti B, Molfetta R, Fionda C, Quatrini L, Stabile H, Lecce M, de Turris V, Ricciardi MR, Petrucci MT, **Cippitelli M**, Gismondi A, Santoni A, Paolini R.

Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells.

**Sci Rep.** 2017 Sep 5;7(1):10445. doi: 10.1038/s41598-017-10403-0. **N° Citations: 18** (Scopus)

20 - Vulpis E, Cecere F, Molfetta R, Soriani A, Fionda C, Peruzzi G, Caracciolo G, Palchetti S, Masuelli L, Simonelli L, D'Oro U, Abruzzese MP, Petrucci MT, Ricciardi MR, Paolini R, **Cippitelli M**, Santoni A, Zingoni A.

Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF- $\kappa$ B axis.

**Oncoimmunology.** 2017 Jan 13;6(3):e1279372. doi: 10.1080/2162402X.2017.1279372. eCollection 2017.

**N° Citations: 69** (Scopus)

21 - Soriani A, Borrelli C, Ricci B, Molfetta R, Zingoni A, Fionda C, Carnevale S, Abruzzese MP, Petrucci MT, Ricciardi MR, La Regina G, Di Cesare E, Lavia P, Silvestri R, Paolini R, **Cippitelli M**, Santoni A.

p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells.

**Oncoimmunology.** 2016 Dec 2;6(1):e1264564. doi: 10.1080/2162402X.2016.1264564. eCollection 2017.

**N° Citations: 20** (Scopus)

22 - Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, Borrelli C, Zitti B, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, **Cippitelli M**.

Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.

**J Hematol Oncol.** 2016 Dec 1;9(1):134. doi: 10.1186/s13045-016-0362-2. **N° Citations: 49** (Scopus)

23 - Pignoloni B, Fionda C, Dell'Oste V, Luganini A, **Cippitelli M**, Zingoni A, Landolfo S, Gribaudo G, Santoni A, Carbone C.

Distinct Roles for Human Cytomegalovirus Immediate Early Proteins IE1 and IE2 in the Transcriptional Regulation of MICA and PVR/CD155 Expression.

**J Immunol.** 2016 Nov 15;197(10):4066-4078. doi: 10.4049/jimmunol.1502527. Epub 2016 Oct 12. **N° Citations: 21** (Scopus)

24 - Zingoni A, Vulpis E, Nardone I, Soriani A, Fionda C, **Cippitelli M**, Santoni A.

Targeting NKG2D and NKp30 Ligands Shedding to Improve NK Cell-Based Immunotherapy.

**Crit Rev Immunol.** 2016;36(6):445-460. doi: 10.1615/CritRevImmunol.2017020166. **N° Citations: 19**

(Scopus)

25 - Fionda C, Abruzzese MP, Santoni A, **Cippitelli M**.

Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer.

**Curr Med Chem.** 2016;23(24):2618-2636. doi: 10.2174/0929867323666160727105101. **N° Citations: 30**

(Scopus)

26 - Quatrini L, Molfetta R, Zitti B, Peruzzi G, Fionda C, Capuano C, Galandrini R, **Cippitelli M**, Santoni A, Paolini R.

Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells.

**Sci Signal.** 2015 Oct 27;8(400):ra108. doi: 10.1126/scisignal.aab2724. **N° Citations: 34** (Scopus)

27 - Fionda C, Abruzzese MP, Zingoni A, Cecere F, Vulpis E, Peruzzi G, Soriani A, Molfetta R, Paolini R, Ricciardi MR, Petrucci MT, Santoni A, **Cippitelli M**.

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.

**Oncotarget.** 2015 Sep 15;6(27):23609-30. doi: 10.18632/oncotarget.4603. **N° Citations: 55** (Scopus)

- 28 - Zingoni A, Cecere F, Vulpis E, Fionda C, Molfetta R, Soriani A, Petrucci MT, Ricciardi MR, Fuerst D, Amendola MG, Mytilineos J, Cerboni C, Paolini R, **Cippitelli M**, Santoni A.  
Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.  
**J Immunol.** 2015 Jul 15;195(2):736-48. doi: 10.4049/jimmunol.1402643. Epub 2015 Jun 12. **N° Citations: 58** (Scopus)
- 29 - Fionda C, Abruzzese MP, Zingoni A, Soriani A, Ricci B, Molfetta R, Paolini R, Santoni A, **Cippitelli M**.  
Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.  
**BMC Cancer.** 2015 Jan 22;15:17. doi: 10.1186/s12885-015-1023-5. **N° Citations: 38** (Scopus)
- 30 - Fionda C, Soriani A, Zingoni A, Santoni A, **Cippitelli M**.  
NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma.  
**Biomed Res Int.** 2015;2015:178698. doi: 10.1155/2015/178698. Epub 2015 Jun 16. **N° Citations: 47** (Scopus)
- 31 - Di Bona D, Scafidi V, Plaia A, Colomba C, Nuzzo D, Occhino C, Tuttolomondo A, Giammanco G, De Grazia S, Montalto G, Duro G, **Cippitelli M**, Caruso C.  
HLA and killer cell immunoglobulin-like receptors influence the natural course of CMV infection.  
**J Infect Dis.** 2014 Oct 1;210(7):1083-9. doi: 10.1093/infdis/jiu226. Epub 2014 Apr 15. **N° Citations: 27** (Scopus)
- 32 - Soriani A, Iannitto ML, Ricci B, Fionda C, Malgarini G, Morrone S, Peruzzi G, Ricciardi MR, Petrucci MT, **Cippitelli M**, Santoni A.  
Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1.  
**J Immunol.** 2014 Jul 15;193(2):950-60. doi: 10.4049/jimmunol.1400271. Epub 2014 Jun 9. **N° Citations: 65** (Scopus)
- 33 - Cerboni C, Fionda C, Soriani A, Zingoni A, Doria M, **Cippitelli M**, Santoni A.  
The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells.  
**Front Immunol.** 2014 Jan 7;4:508. doi: 10.3389/fimmu.2013.00508. eCollection 2014 Jan 7. **N° Citations: 87** (Scopus)
- 34 - Soriani A, Fionda C, Ricci B, Iannitto ML, **Cippitelli M**, Santoni A.  
Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma.  
**Oncoimmunology.** 2013 Dec 1;2(12):e26663. doi: 10.4161/onci.26663. Epub 2013 Oct 22. **N° Citations: 33** (Scopus)
- 35 - Fionda C, Malgarini G, Soriani A, Zingoni A, Cecere F, Iannitto ML, Ricciardi MR, Federico V, Petrucci MT, Santoni A, **Cippitelli M**.  
Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3.  
**J Immunol.** 2013 Jun 15;190(12):6662-72. doi: 10.4049/jimmunol.1201426. Epub 2013 May 17. **N° Citations: 51** (Scopus)
- 36 - Quinci AC, Vitale S, Parretta E, Soriani A, Iannitto ML, **Cippitelli M**, Fionda C, Bulfone-Paus S, Santoni A, Di Rosa F.  
IL-15 inhibits IL-7R $\alpha$  expression by memory-phenotype CD8<sup>+</sup> T cells in the bone marrow.  
**Eur J Immunol.** 2012 May;42(5):1129-39. doi: 10.1002/eji.201142019. **N° Citations: 20** (Scopus)

37 - Nappi F, Chiozzini C, Bordignon V, Borsetti A, Bellino S, **Cippitelli M**, Barillari G, Caputo A, Tyagi M, Giacca M, Ensoli B.

Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation-independent mechanism which requires binding of Tat to viral particles.

**J Gene Med.** 2009 Nov;11(11):955-65. doi: 10.1002/jgm.1381. **N° Citations: 14** (Scopus)

38 - Fionda C, Soriani A, Malgarini G, Iannitto ML, Santoni A, **Cippitelli M**.

Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.

**J Immunol.** 2009 Oct 1;183(7):4385-94. doi: 10.4049/jimmunol.0901797. Epub 2009 Sep 11. **N° Citations: 66** (Scopus)

39 - Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, **Cippitelli M**, Fionda C, Petrucci MT, Guarini A, Foà R, Santoni A.

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype.

**Blood.** 2009 Apr 9;113(15):3503-11. doi: 10.1182/blood-2008-08-173914. Epub 2008 Dec 19. **N° Citations: 298** (Scopus)

40 - Fionda C, Nappi F, Piccoli M, Frati L, Santoni A, **Cippitelli M**.

Inhibition of trail gene expression by cyclopentenonic prostaglandin 15-deoxy-delta12,14-prostaglandin J2 in T lymphocytes.

**Mol Pharmacol.** 2007 Nov;72(5):1246-57. doi: 10.1124/mol.107.038042. Epub 2007 Aug 2. **N° Citations: 13** (Scopus)

41 - Cerboni C, Zingoni A, **Cippitelli M**, Piccoli M, Frati L, Santoni A.

Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis.

**Blood.** 2007 Jul 15;110(2):606-15. doi: 10.1182/blood-2006-10-052720. Epub 2007 Apr 3. **N° Citations: 202** (Scopus)

42 - Fionda C, Nappi F, Piccoli M, Frati L, Santoni A, **Cippitelli M**.

15-deoxy-Delta12,14-prostaglandin J2 negatively regulates rankl gene expression in activated T lymphocytes: role of NF-kappaB and early growth response transcription factors.

**J Immunol.** 2007 Apr 1;178(7):4039-50. doi: 10.4049/jimmunol.178.7.4039. **N° Citations: 14** (Scopus)

43 - Di Bona D, **Cippitelli M**, Fionda C, Cammà C, Licata A, Santoni A, Craxi A.

Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway.

**J Hepatol.** 2006 Aug;45(2):271-9. doi: 10.1016/j.jhep.2006.01.037. Epub 2006 Mar 9. **N° Citations: 81** (Scopus)

44 - **Cippitelli M**, Fionda C, Di Bona D, Piccoli M, Frati L, Santoni A.

Hyperthermia enhances CD95-ligand gene expression in T lymphocytes.

**J Immunol.** 2005 Jan 1;174(1):223-32. doi: 10.4049/jimmunol.174.1.223. **N° Citations: 32** (Scopus)

45 - **Cippitelli M**, Fionda C, Di Bona D, Lupo A, Piccoli M, Frati L, Santoni A.

The cyclopentenone-type prostaglandin 15-deoxy-delta 12,14-prostaglandin J2 inhibits CD95 ligand gene expression in T lymphocytes: interference with promoter activation via peroxisome proliferator-activated receptor-gamma-independent mechanisms.

**J Immunol.** 2003 May 1;170(9):4578-92. doi: 10.4049/jimmunol.170.9.4578. **N° Citations: 30** (Scopus)

46 - **Cippitelli M**, Fionda C, Di Bona D, Di Rosa F, Lupo A, Piccoli M, Frati L, Santoni A.

Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes.

**J Immunol.** 2002 Feb 1;168(3):1154-66. doi: 10.4049/jimmunol.168.3.1154. **N° Citations: 66** (Scopus)

- 47 - Ricca A, Biroccio A, Trisciuglio D, **Cippitelli M**, Zupi G, Del Bufalo D.  
relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells.  
*Br J Cancer*. 2001 Dec 14;85(12):1914-21. doi: 10.1054/bjoc.2001.2174. **N° Citations: 40** (Scopus)
- 48 - Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, **Cippitelli M**.  
bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7(ADR) breast-cancer cells.  
*Int J Cancer*. 2000 Apr 15;86(2):188-96. doi: 10.1002/(sici)1097-0215(20000415)86:2<188 N° Citations: **91** (Scopus)
- 49 - Mainiero F, Gismondi A, Soriani A, **Cippitelli M**, Palmieri G, Jacobelli J, Piccoli M, Frati L, Santoni A.  
Integrin-mediated ras-extracellular regulated kinase (ERK) signaling regulates interferon gamma production in human natural killer cells.  
*J Exp Med*. 1998 Oct 5;188(7):1267-75. doi: 10.1084/jem.188.7.1267. **N° Citations: 62** (Scopus)
- 50 - **Cippitelli M**, Santoni A.  
Vitamin D3: a transcriptional modulator of the interferon-gamma gene.  
*Eur J Immunol*. 1998 Oct;28(10):3017-30. doi: 10.1002/(SICI)1521-4141(199810)28:10<3017 N° Citations: **241** (Scopus)
- 51 - D'Ambrosio D, **Cippitelli M**, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R, Sinigaglia F, Panina-Bordignon P.  
Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene.  
*J Clin Invest*. 1998 Jan 1;101(1):252-62. doi: 10.1172/JCI1050. **N° Citations: 589** (Scopus)
- 52 - Sica A, Dorman L, Viggiano V, **Cippitelli M**, Ghosh P, Rice N, Young HA.  
Interaction of NF-kappaB and NFAT with the interferon-gamma promoter.  
*J Biol Chem*. 1997 Nov 28;272(48):30412-20. doi: 10.1074/jbc.272.48.30412. **N° Citations: 355** (Scopus)
- 53 - Curiel RE, Lahesmaa R, Subleski J, **Cippitelli M**, Kirken RA, Young HA, Ghosh P.  
Identification of a Stat-6-responsive element in the promoter of the human interleukin-4 gene.  
*Eur J Immunol*. 1997 Aug;27(8):1982-7. doi: 10.1002/eji.1830270823. **N° Citations: 42** (Scopus)
- 54 - Cippitelli M, Ye J, Viggiano V, Sica A, Ghosh P, Gulino A, Santoni A, Young HA.  
Retinoic acid-induced transcriptional modulation of the human interferon-gamma promoter.  
*J Biol Chem*. 1996 Oct 25;271(43):26783-93. doi: 10.1074/jbc.271.43.26783. **N° Citations: 50** (Scopus)
- 55 - Ye J, **Cippitelli M**, Dorman L, Ortaldo JR, Young HA.  
The nuclear factor YY1 suppresses the human gamma interferon promoter through two mechanisms: inhibition of AP1 binding and activation of a silencer element.  
*Mol Cell Biol*. 1996 Sep;16(9):4744-53. doi: 10.1128/MCB.16.9.4744. **N° Citations: 154** (Scopus)
- 56 - Ghosh P, Sica A, **Cippitelli M**, Subleski J, Lahesmaa R, Young HA, Rice NR.  
Activation of nuclear factor of activated T cells in a cyclosporin A-resistant pathway.  
*J Biol Chem*. 1996 Mar 29;271(13):7700-4. doi: 10.1074/jbc.271.13.7700. **N° Citations: 113** (Scopus)
- 57 - Ghosh P, Komschlies KL, **Cippitelli M**, Longo DL, Subleski J, Ye J, Sica A, Young HA, Wiltrout RH, Ochoa AC.  
Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth.  
*J Natl Cancer Inst*. 1995 Oct 4;87(19):1478-83. doi: 10.1093/jnci/87.19.1478. **N° Citations: 113** (Scopus)

58 - **Cippitelli M**, Sica A, Viggiano V, Ye J, Ghosh P, Birrer MJ, Young HA.  
Negative transcriptional regulation of the interferon-gamma promoter by glucocorticoids and dominant negative mutants of c-Jun.

**J Biol Chem.** 1995 May 26;270(21):12548-56. doi: 10.1074/jbc.270.21.12548. **N° Citations: 111** (Scopus)

59 - Tubaro A., Stroppacciaro A., Velotti F., Bossola P.C., Cusumano G., Vicentini C., De Carli P., Ruco L., Santoni A., Cancrini A., Cancrini M., Cippitelli M., Palmer P.A., Miano L.

Local Immunotherapy of Superficial Bladder Cancer by Intravesical Instillation of Recombinant Interleukin-2.

**Eur Urol** 1995;28:297-303 <https://doi.org/10.1159/000475070> **N° Citations: 24** (Scopus)

60 - Ye J, Ghosh P, **Cippitelli M**, Subleski J, Hardy KJ, Ortaldo JR, Young HA.

Characterization of a silencer regulatory element in the human interferon-gamma promoter.

**J Biol Chem.** 1994 Oct 14;269(41):25728-34. **N° Citations: 64** (Scopus)


61 - Velotti F, Giuffrida A, **Cippitelli M**, Stoppacciaro A, Tubaro A, Ruco L, Santoni A.

Soluble and cell-associated IL-2 receptor (IL-2R) after local immunotherapy with recombinant interleukin-2 (rIL-2).

**Pharmacol Res.** 1992 Sep;26 Suppl 2:52-3. doi: 10.1016/1043-6618(92)90595-3. **N° Citations: /** (Scopus)

**Luogo e data:** Roma, 22/10/2021

**Firma** .....



(non soggetta ad autentica ai sensi dell'art. 39 del D.P.R. 28.12.2000, n. 445)